Innovation I: First Clinical Experience with Targeted Renal Nerve Demodulation (TREND-1): Using a Neurotropic Agent for the Treatment of Sympathetic Hypertension - Mark Wholey, MD

↳ This is a section part of Moment: CRT 2016 Technology & Innovation - Cardiovascular Innovations for CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$6.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Innovation I: First Clinical Experience with Targeted Renal Nerve Demodulation (TREND-1): Using a Neurotropic Agent for the Treatment of Sympathetic Hypertension presented by Mark Wholey, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$6.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physicians with an interest in Cardiovascular Innovations

Session Name: Cardiovascular Innovations for CRT 2016

Track: Technology & Innovation

Learning Objectives

Updates in the latest Cardiovascular Innovations

Other Components in this Moment

Overview

Innovation I: First Clinical Experience with Targeted Renal Nerve Demodulation (TREND-1): Using a Neurotropic Agent for the Treatment of Sympathetic Hypertension - Mark Wholey, MD

Innovation III: The Use of the CrossLock™ Catheter in a Patient with Critical Limb Ischemia and a Popliteal Occlusion - Rich Heuser, MD, FSCAI

Innovation IV: Intravascular Assessment of Arterial Diseases Using Compensated Optical Coherence Tomography - Nicholas Foin

Innovation V: On-Demand Urgent Care - Regina Druz, MD, FACC